Log in
Enquire now
Karyopharm Therapeutics

Karyopharm Therapeutics

A pharmaceutical company that develops drugs to treat cancer and other major disease

OverviewStructured DataIssuesContributors

Contents

karyopharm.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biotechnology
Biotechnology
Biomedical engineering
Biomedical engineering
Cancer
Cancer
Therapy
Therapy
Oncology
Oncology
Drug discovery
Drug discovery
Therapeutics
Therapeutics
...
Location
Newton, Massachusetts
Newton, Massachusetts
Natick, Massachusetts
Natick, Massachusetts
United States
United States
B2X
B2B
B2B
CEO
‌
Richard Paulson
0
Founder
Sharon Shacham
Sharon Shacham
Ronald A. DePinho
Ronald A. DePinho
AngelList URL
angel.co/karyopharm...herapeutics
Pitchbook URL
pitchbook.com/profiles.../51225-40
Legal Name
Karyopharm Therapeutics Inc.
Date Incorporated
2008
Number of Employees (Ranges)
201 – 5000
Phone Number
+498954848600
+161765806000
Number of Employees
4810
Full Address
4 Ariel Sharon Street Givatayim, Israel0
Franziska-Bilek-Weg 9 80339 Munich0
85 Wells Ave., 2nd floor Newton, MA 02459, USA0
85 WELLS AVE FL 2 NEWTON, MA 02459 UNITED STATES
CIK Number
1,503,8020
Place of Incorporation
Delaware
Delaware
0
Investors
Delphi Ventures
Delphi Ventures
DUNS Number
0613176800
IRS Number
263,931,7040
Founded Date
2008
0
Total Funding Amount (USD)
88,200,000
Latest Funding Round Date
May 20, 2013
Stock Symbol
KPTI0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Peter K Honig
0
‌
Chen Schor
0
‌
Christy J. Oliger
0
‌
Michael G. Kauffman
0
‌
Barry E. Greene
0
‌
Garen Bohlin
0
‌
Mansoor Raza Mirza
0
Deepa R. Pakianathan
Deepa R. Pakianathan
0
CFO
‌
Michael Mason (entrepreneur)
0
Latest Funding Type
Series B
Series B
NAICS Code
325,4120
CAGE Code
7FSV20
Patents Assigned (Count)
1
Wellfound ID
karyopharm-therapeutics
Country
United States
United States
Headquarters
Newton, Massachusetts
Newton, Massachusetts
0

Other attributes

Company Operating Status
Active
Contact Page URL
karyopharm.com/contact-us/
SIC Code
2,8340
Ticker Symbol
KPTI

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, Massachusetts that was founded in 2008 by Ronald A. DePinho and Sharon Shacham.

The company focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1.

Products

Karyopharm's leading product candidate is Selinexor, an oral, reversible SINE that specifically blocks XPO1. It is being evaluated in multiple Phase 2 and 3 clinical trials in patients with relapsed or refractory hematological and solid tumor malignancies. Selinexor has been granted Orphan Drug Designation in both the US and the EU in multiple myeloma. It is also being investigated in clinical Phase 3 clinical studies for advanced unresectable dedifferentiated liposarcoma and endometrial cancer. Karyopharm is preparing for its first potential U.S. commercial launch with Selinexor sometime in 2019.

Other products in the company's pipeline include, Eltanexor, Verdinexor, and KPT-9274. Eltanexor is an investigational second-generation SINE compound that is designed to selectively block XPO1. Similar to Selinexor, it is also intended to serve as a treatment for cancer indications, including myelodysplastic syndrome, colorectal cancer, and castrate-resistant prostate cancer.

Verdinexor is intended to be a potential oral antiviral treatment for influenza. It is also being evaluated for the treatment of lymphomas and other cancers in dogs. KPT-9274 is an orally bioavailable small molecule that is a non-competitive dual modulator of PAK4 and NAMPT for the treatment of patients with advanced solid malignancies or non-Hodgkin's Lymphoma.

Funding
Series A

On November 2, 2011 Karyopharm Therapeutics completed their series A funding round with $10 million in funding from Chione.

Series B

On May 20, 2017 Karyopharm Therapeutics completed their series B funding round with $48.5 million in capital from Delphi Ventures.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Karyopharm Therapeutics Announces Management Change

Karyopharm Therapeutics Inc.

https://globenewswire.com/news-release/2018/10/26/1627740/0/en/Karyopharm-Therapeutics-Announces-Management-Change.html

Web

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

CNBC

https://www.cnbc.com/2018/05/02/globe-newswire-karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock.html

Web

References

Find more companies like Karyopharm Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.